PLENARY LECTURE: Modeling cancer in the mouse
Tyler Jacks, PhD
Director, Koch Institute for Integrative Cancer Research
Dr. Tyler Jacks is a world leader in the field of cancer genetics and is known for his ground-breaking work on the development of genetically-engineered mouse models of cancer (GEMMs). Over the course of his academic career, he has published over 200 peer- reviewed papers along with numerous review articles and book chapters. Dr. Jacks graduated magna cum laude with a BA in Biology in 1983 from Harvard College before becoming a graduate student in the laboratory of Dr. Harold Varmus at the University of California, San Francisco, where he showed that ribosomal frameshifting during translation gives rise to the gag-pol protein of the Rous sarcoma virus, HIV-1 virus and mouse mammary tumor virus. He went on to demonstrate that a stem-loop structure and RNA sequence making up the frameshift site are required for efficient frameshifting in vitro. In 1998, Dr. Jacks returned to Cambridge, Massachusetts, to join Dr. Robert Weinberg’s group as a post-doctoral fellow at the Whitehead Institute, where he developed several GEMMs, including the Rb, p53 and Nf1 mice. In 1992, Dr. Jacks became an assistant professor in the MIT Department of Biology and a member of the MIT Center for Cancer Research, which became the Koch Institute for Integrative Cancer Research at MIT in 2011. Currently, he is the David H. Koch Professor of Biology, Director of the Koch Institute for Integrative Cancer Research at MIT and an Investigator at the Howard Hughes Medical Institute. The Jacks lab has focused on developing new methods for the construction and characterization of GEMMs of human cancer. His group has produced GEMMs with constitutive and conditional mutations in several tumor suppressor genes, oncogenes, and genes involved in cell cycle control and apoptosis. Using these strains, the laboratory has developed models of various human tumor syndromes and cancer types, including Li-Fraumeni Syndrome, neurofibromatosis type 1, astrocytoma, retinoblastoma, pancreatic cancer, invasive colon cancer, soft tissue sarcoma, endometriosis, ovarian cancer and lung adenocarcinoma. These GEMMS have been used to examine the mechanism of tumor initiation and progression, to uncover the molecular, genetic and biochemical relationship to the human diseases, as tools to study response and resistance to chemotherapy, and to explore methods in molecular imaging and early detection of cancer. His laboratory has also extensively studied human tumor-derived cells, determined protein function in these cells, and related gene expression patterns in human cancers to their studies in mouse models. Novel pathways and processes that are critical for the progression of cancer have been discovered during these investigations.

In recent years, the Jacks lab has moved into the burgeoning area of tumor immunology and utilizing GEMMs to understand the interactions between the immune system and cancer. In particular the lab has developed a mouse model of lung adenocarcinoma that harbors mutations in the Kras and p53 genes and that also expresses model T cell antigens, which serve as targets for tumor-specific T cells and stimulate anti-tumor immune responses. These models offer a unique platform for investigating how anti-tumor immune responses shape tumor gene expression, and importantly how tumor evasion mechanisms contribute to the development of advanced disease. Moreover, they are invaluable preclinical models for testing immunotherapeutics, as single agents, or in combinations with traditional or targeted therapies.

Dr. Jacks has received numerous awards and honors for his contributions to the study of cancer genetics including the AACR Outstanding Achievement Award, the Amgen Award from the American Society of Biochemistry and Molecular Biology, the Chestnut Hill Award for Excellence in Medical Research, the Paul Marks Prize for Cancer Research, the Hope Funds for Cancer Research Award for Excellence and the Sergio Lombroso Award in Cancer Research. He was also a 2013 honoree of the MGH Cancer Center’s One Hundred celebration. Dr. Jacks served both as Chair and Member of the National Cancer Advisory Board at the National Cancer Institute as well as a member on the Board of Directors of the American Association for Cancer Research (AACR), where he was elected President of the organization in 2009. Dr. Jacks was also elected to the National Academy of Sciences, the Institute of Medicine of the National Academies, the American Academy of Arts and Sciences and the inaugural class of Fellows of the AACR Academy. Dr. Jacks serves as an advisor to several biotechnology and pharmaceutical companies. In 2015, he was the recipient of the Killian Award, the highest honor the MIT faculty can bestow upon one of its members. He is currently serving as director of the Blue Ribbon Panel for the National Cancer Moonshot Initiative, a working group of the National Cancer Advisory Board that provides expert advice to the task force lead by former Vice-President Biden.


SYMPOSIUM 1: Radiation-induced GI Syndrome

Cullen Taniguchi MD, PhD
MD Anderson Cancer Center
Jian Yu, PhD
University of Pittsburgh Medical Center

SYMPOSIUM 2: Radiation dosimetry: In patients and phantoms
Mark Oldham, PhD
Duke University
 Brian Pogue, PhD
Thayer School of Engineering
at Dartmouth

SYMPOSIUM 3: Mechanisms of cell death after radiation

Kristopher Sarosiek, PhD
Harvard T.H. Chan School of Public Health 

Daohong Zhou, MD 
University of Arkansas for Medical Science 

SYMPOSIUM 4: Hypofractionation: from pre-clinical models to clinical trials
Navita Somaiah, MD, PhD
The Institute of Cancer Research, London
SYMPOSIUM 5: Genomics of normal tissue toxicity and tumor response to radiation
Kent Mouw MD, PhD 
Dana-Farber Cancer Institute
Mohamed Abazeed MD, PhD 
Cleveland Clinic

SYMPOSIUM 6: Hypoxia and ER stress

Constantinos Koumenis, PhD
University of Pennsylvania

Marianne Koritzinsky, PhD
University Health Network
SYMPOSIUM 7: Imaging and circulating biomarkers of radiation response
Max Diehn MD, PhD
Stanford Medicine
Andrew Wang, MD 
University of North Carolina
School of Medicine
SYMPOSIUM 8: Radionuclides for imaging, therapy, and dosimetry
Ana Ponce Kiess MD, PhD 
Johns Hopkins Medicine
David Mankoff MD, PhD
University of Pennsylvania
Rebecca Abergel, PhD
Lawrence Berkeley Laboratory
SYMPOSIUM 9: Chromatin biology and radiation response
Brendan Price, PhD
Dana-Farber Cancer Institute

Tej Pandita, PhD
Houston Methodist

SYMPOSIUM 10: Joint Session (CRH)Space radiation and cancer risk
 Mike Weil, PhD
Colorado State University
 Sylvain Costes, PhD


Francis A. Cucinotta, PhD
Dr. Francis A. Cucinotta is a Professor of Health Physics at the University of Nevada, Las Vegas. Dr. Cucinotta received his Doctorate degree in nuclear physics from Old Dominion University in 1988. He worked at NASA Johnson Space Center from 1997-2013 as the Radiological Health Officer, Space Radiation Project Manager and Chief Scientist. He developed the astronaut exposure data base of organ doses and cancer risk estimates for all human missions from Mercury to the International Space Station (ISS). He was NASA’s manager for construction and operations of the NASA Space Radiation Laboratory (NSRL) from 1999-2013. Dr. Cucinotta worked on radiation safety in NASA’s Mission Control Center for the Space Shuttle and ISS programs in 1989-1990, and 2000-2006. He has published over 350 peer-reviewed journal articles in a broad range of topical areas, including nuclear and space physics, track structure, biophysics models of DNA damage repair and neuronal effects, biodosimetry, radiation cataracts, and risk assessment models for cancer and acute health effects. Dr. Cucinotta is a past President of the Radiation Research Society (2013-2014), and a Council Member of the National Council of Radiation Protection and Measurements (NCRP).

James DeGregori, PhD
University of Colorado Denver
School of Medicine
Amitava Adhikary, PhD
Oakland University
Joseph Deasy, PhD
Memorial Sloan Kettering Cancer Center
Marjan Boerma, PhD
University of Arkansas for
Medical Science
Scott Floyd MD, PhD 
Duke University School of Medicine
PLENARY LECTURE: Cancer etiology and its mutational signatures

Assistant Professor, Johns Hopkins University
Dr. Cristian Tomasetti is an Associate Professor in the Division of Biostatistics and Bioinformatics of the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins School of Medicine, and in the Department of Biostatistics of the Johns Hopkins Bloomberg School of Public Health.
His work is recognized internationally for his paradigm-shift contributions to the current understanding of cancer etiology and tumor evolution. He is also actively working on the development of novel methodologies for the estimation of cancer risk, as well as on the development of algorithms for the early detection of cancer via screening.
Dr. Tomasetti earned a Ph.D. in Applied Mathematics from the University of Maryland, College Park (Dec. 2010). He was then a Ruth L. Kirschstein National Research Service Award Postdoctoral Fellow in the Department of Biostatistics of the Harvard School of Public Health and in the Department of Biostatistics and Computational Biology of the Dana-Farber Cancer Institute (Jan 2011 – Jun 2013). Since then he has been a faculty member at Hopkins.

SYMPOSIUM 11: Pre-clinical mechanisms of radiation and immunotherapy

Andy Minn MD, PhD
University of Pennsylvania

Elizabeth Repasky, PhD 
Roswell Park Comprehensive Cancer Center
SYMPOSIUM 12: Dose rate and radiation toxicity
Marie-Catherine Vozenin, PhD
Peter Maxim, PhD 
Stanford University Medical Center
SYMPOSIUM 13: A tribute and celebration: the contributions and impact of Michael Fry to Radiation Research
Eleanor Blakely, PhD
Lawrence Berkeley National Laboratory
Amy Kronenberg, ScD
Lawrence Berkeley National Laboratory
John Boice, ScD
Vanderbilt-Ingram Cancer Center
Robert Ullrich, MD
University of Texas Medical Branch 
SYMPOSIUM 14: Reactive oxygen species, redox and metabolism
Julie Schwarz MD, PhD
Washington University School of Medicine
Alec Kimmelman MD, PhD
NYU Langone Health
SYMPOSIUM 15: Track structure and Monte Carlo modeling of biological effects
José Ramos-Méndez, PHD
University of California- San Francisco
Marta Bueno, PhD
PRESIDENTIAL SYMPOSIUM: Future radiobiology for advance radiotherapies

Michael Baumann
German Cancer Research Center
Marco Durante, PhD
Trento Institute for Fundamentals
Physics Applications

Dorthe Schaue, PhD
UCLA Health
Soren Bentzen, PhD, DMSc
University of Maryland
School of Medicine


Jan Schuemann, PhD
Dr. Schuemann is a radiation bio-physicist specializing in Monte Carlo (MC) simulation research for proton therapy and radiobiology. After spending 10 years in experimental high-energy particle physics and neutrino physics in Germany, Taiwan and Japan, he transitioned to medical physics as a post-doctorate in 2010 joining the team at the Massachusetts General Hospital/Harvard Medical School in Boston. Two years later, he joined the research team as Assistant Radiation Bio-Physicist at MGH and Instructor at HMS. In 2015, he started his current appointment as Assistant Professor of Radiation Oncology at MGH/HMS and Head of the Multi Scale MC Modeling Lab.

His research focuses on improving clinical treatment through the use of MC methods at multiple scales. At the macroscopic scale, he applies MC simulations to improve the accuracy of clinical dose and RBE distributions in patients. At the nanometer scale, he studies the biological effects of radiation on cell and sub-cellular components to better understand the underlying mechanisms of radiation effects with the goal to develop new ideas such as nanoparticle enhancement to improve radiation therapy outcome.

Gianluca Lattanzi, PhD
University of Trento
Walter Tinganelli, PhD
Trento Institute for Fundamentals
Physics Applications
David Brenner, PhD, DSc
Columbia University Medical Center
Elaine Zeman, PhD
UNC School of Medicine
Gayle Woloschak, PhD
Northwestern University Feinberg
School of Medicine

PLENARY LECTURE: Radiation and immunotherapy

Sandra Demaria, MD
Sandra Demaria, MD, a native of Turin, Italy, obtained her MD from the University of Turin. She then moved to New York City for her postdoctoral training in immunology is a Damon Runyon-Walter Winchell Cancer Research Fund awardee, followed by a residency in anatomic pathology at New York University School of Medicine. She remained on the faculty at NYU School of Medicine, where she was an attending pathologist in the breast cancer service, an independent investigator and co-leader of the Cancer Immunology program of NYU Cancer Institute until 2015, raising to the rank of Professor.

She is currently Professor of Radiation Oncology and Pathology at Weill Cornell Medicine Medical College where she leads a NIH-funded laboratory. Dr. Demaria is internationally known for her studies demonstrating the synergy of local radiation therapy with different immunotherapeutic agents in pre-clinical models of cancer. She was the first to show that radiotherapy can convert breast tumors unresponsive to immune checkpoint inhibitors into responsive ones. She has been working in partnership with Dr. Silvia Formenti for the past decade to develop a novel treatment paradigm exploiting the immune adjuvant effects of radiotherapy and translate the pre-clinical findings to the clinic.

Dr. Demaria's current work is aimed at identifying the molecular mechanisms that regulate ionizing radiation’s ability to generate an in situ tumor vaccine in preclinical tumor models as well as cancer patients treated in clinical trials testing various
combinations of radiation and immunotherapy. As a breast cancer pathologist Dr. Demaria has also studied the immunological microenvironment of breast cancer in patients, and therapeutic strategies to modulate the immune infiltrate in preclinical breast cancer models. She holds leadership positions in national professional societies, including the Society for Immunotherapy of Cancer (SITC) where she currently serves on the Board, and is a member of the Steering Committee of AACR Cancer Immunology Working Group. She is also an elected member of the European Academy for Tumor Immunology (EATI), and serves in the editorial board of several journals, including
Radiation Research, The Journal of Immunology, Clinical Cancer Research, and Journal for ImmunoTherapy of Cancer.

SYMPOSIUM 16: Radiation biology of model organisms: flies, worms, and fish
Don Fox, PhD
Duke School of Medicine
Ding Xue, PhD
University of Colorado- Boulder
SYMPOSIUM 17: DNA damage response and DNA repair
Maria Jasin, PhD
Memorial Sloan Kettering Cancer Center
 Thomas Helleday
Karolinska Institutet
SYMPOSIUM 18:Co-sponsored by ASTRO: Clinical trials of radiation therapy and immunotherapy 
Jim Welsh, MD
MD Anderson Cancer Center
Kristina Young, MD, PhD
Oregon Health & Science University
Ann Klopp, MD, PhD
MD Anderson Cancer Center

SYMPOSIUM 19: Radiomics, radiogenomics and artificial intelligence
Barry Rosenstein, MD, PhD 
NYU School of Medicine
Javier Torres-Roca MD 
Moffitt Cancer Center
SYMPOSIUM 20: Medical countermeasures of radiation (mitigators)

John Chute, MD
UCLA Health
Christie Orschell, PhD
Indiana University
School of Medicine

Christopher Bakkenist, PhD
University of Pittsburgh
Medical Center

Piero Fossati, PhD
Claudia Wiese, PhD
Colorado State University
David Yu MD, PhD
Emory University
School of Medicine
Polly Chang, PhD
National Council on Radiation Protection & Measurement
James Lederer, PhD
Harvard Medical School 
PLENARY LECTURE: Biologically motivated treatment planning in proton therapy

Harold Paganetti, PhD
Director of Physics Research, Professor Massachusetts General Hospital
Harald Paganetti, PhD, is the Director of Physics Research at the Department of Radiation Oncology at Massachusetts General Hospital and a Professor of Radiation Oncology at Harvard Medical School. He received his PhD in experimental nuclear physics in 1992 from the Rheinische-Friedrich-Wilhelms University in Bonn, Germany, and has been working in radiation therapy research on experimental as well as theoretical aspects since 1994.

He is internationally recognized as an authority on proton therapy and specifically on Monte-Carlo simulations of dose and biological effects, the latter including modeling of clinical relative biological effectiveness as well as late effects. He has authored and co-authored more than 120 peer-reviewed publications and has edited a book on Proton Therapy Physics. For his research leadership he received the 2013 A. Clifford Barger Excellence in Mentoring Award from Harvard Medical School. Dr. Paganetti has been awarded numerous research grants from the National Cancer Institute.

He serves on the editorial boards for the International Journal of Radiation Oncology, Biology, Physics as well as Technology in Cancer Research and Treatment. He is a member of numerous task groups and committees for various associations such as the American Association of Physicists in Medicine. Notably he is a member of the Radiation Physics Committee of the American Society for Therapeutic Radiology and Oncology. From 2009 to 2012 he was the Science Chair of the International Organization for Medical Physics. He is also a member of the Radiation Therapeutics and Biology Study Section at the National Cancer Institute.

SYMPOSIUM 21: Stem cells and radiation toxicity
Isabelle Lombaert, PhD
University of Michigan 
SYMPOSIUM 22: Radiation Chemistry
Sylwia Ptasinska, PhD
University of Notre Dame 
Ian Carmichael, PhD
University of Notre Dame
Mohamad Al-Sheikhly, PhD
University of Maryland
SYMPOSIUM 23: Radiation modifiers (protectors and sensitizers)
Ranjit Bindra, MD, PhD
Yale University School of Medicine
Meredith Morgan, PhD
University of Michigan
SYMPOSIUM 24: Proton and carbon ion radiotherapy
Piero Fossati
Thomas DeLaney, MD
Harvard Medical School

SYMPOSIUM 25: Small animal irradiation

Katia Parodi
LMU Munich
Phuoc Tran, MD, PhD
Johns Hopkins Medicine

PAINTER DEBATE: Tumor initiating cell, not the microenvironment, regulates radiation carcinogenesis
This house believes that the biological mechanisms that underlie cancer development are sufficient to dismiss linear-no-threshold (LNT) modeling of cancer risk

Francis A. Cucinotta, PhD
University of Nevada, Las Vegas
Mary Helen Barcellos-Hoff, PhD
UCSF School of Medicine


Amrita Cheema, PhD
Amrita Cheema, PhD, is a professor of Oncology and Biochemistry at Georgetown University Medical Center. She also co-directs the Waters Center of Innovation in Metabolomics at GUMC. Her extramurally funded research program is focused on delineating small molecule biomarkers that are predictive of exposure to ionizing radiation as well for adverse outcomes of radiotherapy. Her laboratory has also developed several tools and workflows for furthering metabolomics based molecular phenotyping for clinical and translational research. Amrita’s work has been documented in more than 40 peer reviewed publications and 5 biomarker patents.

PRESIDENTIAL SYMPOSIUM 2: p53 in radiation response and tumor suppression

Michael Kastan, MD, PhD
Duke Cancer Institute
Allan Balmain BSc, PhD
UCSF School of Medicine
Laura Attardi, PhD
Stanford Medicine
Andrei Gudkov, PhD, DSci
Roswell Park Comprehensive
Cancer Center

380 Ice Center Lane, Suite C | Bozeman, MT 59718 | 1.877.216.1919
Member & Exhibitor Services: Audrey Rinehart |
1.877.216.1919  |